Requires health insurance coverage and limits cost sharing for certain birth control methods.
Impact
The passage of S263 would represent a significant change in state law, expanding the requirements for health insurance coverage in New Jersey by including male sterilization in addition to current coverage for female contraceptives. Health plans would need to implement these changes within 90 days after enactment, applying to all policies issued or renewed after the effective date. This could lead to increased access to reproductive health services and potentially lower healthcare costs for individuals related to contraceptive use.
Summary
Senate Bill S263 aims to amend existing laws to require health insurance providers in New Jersey to cover prescription female contraceptives and male sterilization procedures without any cost-sharing requirements such as deductibles, coinsurance, or copayments. The bill is intended to enhance access to birth control methods, ensuring that these essential health services are more easily available to all individuals under health plans in the state. This legislative move aligns with broader efforts to promote reproductive health rights and support family planning initiatives.
Contention
Notably, the bill has sparked discussions around the implications of mandating such coverage, especially from religious organizations which may object to providing insurance coverage for contraception based on their beliefs. The bill includes provisions for religious employers to request exclusions if the required coverage conflicts with their bona fide religious beliefs, thus aiming to balance the provision of healthcare with religious freedoms. These discussions highlight the ongoing debate between reproductive rights and religious liberties in healthcare policy.
Requires Medicaid provide health benefits coverage, and places certain requirements on insurers and State Health Benefits Program regarding existing mandate on health benefits coverage, for certain over-the-counter contraceptives.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.